Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Gemma Gatta*, Laura Botta, María José Sánchez, Lesley Ann Anderson, Daniela Pierannunzio, Lisa Licitra, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. AareleidN. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A. V. Guizard, J. Faivre, A. M. Bouvier, P. Arveux, M. Maynadié, A. S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

318 Citations (Scopus)


Background Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. Methods We analysed about 250,000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub-site. Results Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five-year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five-year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx). Conclusions This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.

Original languageEnglish
Pages (from-to)2130-2143
Number of pages14
JournalEuropean Journal of Cancer
Issue number15
Early online date26 Sept 2015
Publication statusPublished - 1 Oct 2015

Bibliographical note

Role of funding source
Compagnia di San Paolo, Fondazione Cariplo Italy, Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and European Commission for two projects: (i) European Action Against Cancer, EPAAC, Joint Action No 20102202, and (ii) ‘Information network on rare cancers’, Grant No. 2000111201.

The funding sources had no role in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.


  • Europe
  • Head and neck cancers
  • Hypopharynx
  • Larynx
  • Nasopharynx
  • Oral cavity
  • Oropharynx
  • Population-based study
  • Survival
  • Tongue


Dive into the research topics of 'Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study'. Together they form a unique fingerprint.

Cite this